2026-01-24 - Analysis Report
**Company Overview**
Eli Lilly is a pharmaceutical company that develops, manufactures, and sells pharmaceutical products.

**Return Rate Comparison**
* Ticker: LLY
* Cumulative Return: 657.30%
* Comparison Stock (VOO): 126.41%
* Divergence: 530.90
* Relative Divergence: 92.20%

The cumulative return of LLY is significantly higher than that of the S&P 500. The divergence between the two is also notable, indicating a strong outperformance by LLY.

**Alpha, Beta Analysis**
| Year     | CAGR | MDD | Alpha | Beta | Cap(B) |
|----------|------|-----|-------|------|-------|
| 2016-2018 | 51.0% | 14.2% | 39.0% | 0.7  | 103.7B |
| 2017-2019 | 54.0% | 12.7% | 28.0% | 0.7  | 117.8B |
| 2018-2020 | 82.0% | 20.0% | 57.0% | 0.7  | 151.4B |
| 2019-2021 | 131.0% | 20.0% | 65.0% | 0.7  | 247.6B |
| 2020-2022 | 176.0% | 20.0% | 170.0% | 0.7  | 328.0B |
| 2021-2023 | 268.0% | 18.3% | 248.0% | 0.5  | 522.6B |
| 2022-2024 | 352.0% | 23.8% | 323.0% | 0.6  | 692.1B |
| 2023-2025 | 452.0% | 33.4% | 377.0% | 0.7  | 963.4B |

The Alpha values indicate a strong outperformance by LLY over the S&P 500, with a relatively stable Beta value indicating a low level of volatility.

**Recent Stock Price Fluctuations**
* Close: $1,064.29
* 5-day SMA: $1,061.98
* 20-day SMA: $1,070.25
* 60-day SMA: $1,025.50

The short-term moving averages indicate a slight downtrend, while the long-term moving average suggests a stable price level.

**RSI, PPO Index Indicators**
* Market Risk Indicator (MRI): 0.70
* RSI: 47.26
* PPO: -0.28
* Delta_Previous_Relative_Divergence: 3.90 (+)
* Expected_Return: 99.30%

The RSI value indicates a slight oversold condition, while the PPO value suggests a bearish trend. The Delta_Previous_Relative_Divergence value indicates an improving trend.

**Recent News & Significant Events**
* [2026-01-21] Why Eli Lilly (LLY) Stock Is Up Today - Yahoo Finance
* [2026-01-21] Eli Lilly: Buy Ahead Of Its Earnings Day (Preview) (NYSE:LLY) - Seeking Alpha
* [2026-01-23] Bernstein Sees Eli Lilly Stock (LLY) Hitting $1,300 Per Share - TipRanks
* [2026-01-20] 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 - MarketBeat
* [2026-01-21] Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot (NYSE:LLY) - Seeking Alpha
* [2026-01-20] Which Pharma Stock Stands Taller Right Now: LLY or PFE? - Yahoo Finance

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
- Opinions: 28
- Target Price (avg/high/low): 1110.71 / 1500.00 / 770.00

**Recent Earnings Analysis**
| Date       | EPS | Revenue |
|------------|-----|---------|
| 2025-10-30 | 6.22 | 17.60B$ |
| 2025-08-07 | 6.3  | 15.56B$ |
| 2025-05-01 | 3.07 | 12.73B$ |
| 2024-10-30 | 1.08 | 11.44B$ |
| 2025-10-30 | 1.08 | 11.44B$ |

The recent earnings have shown a significant improvement in revenue and EPS.

**Financial Information**
**Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | 17.60B$ | 82.91% |
| 2025-06-30 | 15.56B$ | 84.27% |
| 2025-03-31 | 12.73B$ | 82.53% |
| 2024-12-31 | 13.53B$ | 82.24% |
| 2024-09-30 | 11.44B$ | 81.02% |

**Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | 23.79B$ | 23.46% |
| 2025-06-30 | 18.27B$ | 30.98% |
| 2025-03-31 | 15.76B$ | 17.50% |
| 2024-12-31 | 14.19B$ | 31.07% |
| 2024-09-30 | 14.24B$ | 6.81% |

The recent financial information indicates a significant improvement in revenue and ROE, with a stable equity level.

**Comprehensive Analysis**
Eli Lilly has shown a strong outperformance over the S&P 500, with a significant improvement in revenue and EPS. The company has a stable equity level and a relatively stable Beta value. However, the RSI value indicates a slight oversold condition, and the PPO value suggests a bearish trend. The recent news and significant events indicate a positive sentiment towards the company, with a potential target price of $1,300.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.